The FDA's clearance for Gracell Biotechnologies' IND application is a significant regulatory milestone that typically leads to positive investor sentiment and can drive the stock price up in the short term. The news directly impacts the company's potential growth and future revenue streams, making it highly relevant and important to investors. The confidence score reflects the typical market reaction to such regulatory advancements, although the actual impact on the stock price can be influenced by broader market conditions and investor perceptions.